Santa Ana Bio, Inc.

Alameda, CA · Founded 2020 · CIK 0001864492 · Biotech · Private

Targeted immunology therapeutics for autoimmune and inflammatory disease

santaana.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$63M
3 Form D · Jun 2024
28 months since last filing
Contracts
—
No federal contracts on record
Patents
10
0 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$8,024,658
Private capital raisedForm D · SEC$35,313,642
Private capital raisedForm D · SEC$19,999,998
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2890Network Music Partners, LLC—$205K
2891Sage Therapeutics—$698M
2892OTHRO THERAPEUTICS, INC.——
2893Santa Ana Bio, Inc.—$63M
2894General Specific Inc.—$1.5M
2895Character Biosciences, Inc.—$57M
2896ANAPTYSBIO INC—$51M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Marcelo BigaloDirector
  • Christine BorowskiDirector
  • Brendan Bulik-SullivanDirector
  • Jerel DavisDirector · Executive Officer
  • Mittie DoyleDirector
  • Peter EmtageDirector · Executive Officer
  • Shinichiro FuseDirector
  • Thomas WoiwodeDirector

Patents

USPTO · 0 granted of 10
  • Antibodies Targeting C-kit And/or Siglec And Uses Thereofapplication
  • Methods And Compositions For Treating Autoimmune, Allergic And Inflammatory Diseasesapplication
  • Methods And Compositions For Treating Autoimmune, Allergic And Inflammatory Diseasesapplication
  • Antibodies Targeting C-kit And/or Siglec And Uses Thereofapplication
  • Antibodies Targeting FCER1, C-kit, And/or Siglec And Use Thereofapplication
  • Methods And Compositions For Treating Autoimmune, Allergic And Inflammatory Diseasesapplication
  • Methods And Compositions For Treating Autoimmune, Allergic And Inflammatory Diseasesapplication
  • Methods And Compositions For Treating Autoimmune, Allergic And Inflammatory Diseasesapplication
  • Antibodies Targeting FCER1, C-kit, And/or Siglec And Use Thereofapplication
  • Methods And Compositions For Treating Autoimmune, Allergic And Inflammatory Diseasesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.